- Supported exchanges /
- AU /
- TYP.AU
Tryptamine Therapeutics Limited (TYP AU) stock market data APIs
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
Tryptamine Therapeutics Limited Financial Data Overview
| 0.054 | |
| 0.048 | |
| - | |
| 0.057 | |
| 0.047 | |
| 0.011-0.057 | |
| 27 342 K | |
| 1 189 M | |
| 0 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Tryptamine Therapeutics Limited Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Tryptamine Therapeutics Limited Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Tryptamine Therapeutics Limited End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
